News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Promedior Announces Presentation of Data at Association for Research in Vision & Ophthalmology Demonstrating that Pentraxin-2 Suppresses Fibrosis, Neovascularization, and Vascular Leak in Retinal Disease Models


5/1/2012 10:51:54 AM

MALVERN, Pa.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that data from preclinical studies of recombinant human Pentraxin-2 (rPTX-2) will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held May 6-10, 2012, in Ft. Lauderdale, FL. The data to be presented highlight the efficacy of recombinant Pentraxin-2 in suppressing choroidal fibrosis and subretinal vascular leakage in independent models of age-related macular degeneration (AMD) and diabetic retinopathy, and confirm the potent effect of Pentraxin-2 on induction of regulatory macrophage activity in the retina.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES